Applications of metabolomics in drug discovery and development

Drugs in R and D

Volumn 9, Issue 5, 2008, Pages 307-322

  Wishart, David S ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

Author keywords

Biomarkers; Drug evaluation; Metabolism; Pharmacokinetics; Small molecules, general

Indexed keywords

BIOLOGICAL MARKER;

DATA BASE; DRUG EFFICACY; DRUG INDUSTRY; DRUG METABOLISM; DRUG MONITORING; DRUG RESEARCH; DRUG TOXICITY; HUMAN; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; METABOLOMICS; NUCLEAR MAGNETIC RESONANCE; PRIORITY JOURNAL; REVIEW;

ANIMALS; BIOLOGICAL MARKERS; CLINICAL TRIALS AS TOPIC; DRUG DISCOVERY; DRUG EVALUATION, PRECLINICAL; HUMANS; METABOLIC DETOXICATION, DRUG; METABOLOMICS; PRODUCT SURVEILLANCE, POSTMARKETING; TECHNOLOGY, PHARMACEUTICAL;

EID: 50149086997     PISSN: 11745886     EISSN: None     Source Type: Journal    
DOI: 10.2165/00126839-200809050-00002     Document Type: Review

References (102)

1. DiMasi JA, Hansen RW, Grabowski HG. The price of innovation: new estimates of drug development costs. J Health Econ 2003; 22: 151-85
2. Frantz S. Pipeline problems are increasing the urge to merge. Nat Rev Drug Discov 2006 Dec; 5 (12): 977-9
3. Bains W. Failure rates in drug discovery and development: will we ever get any better? Drug Disc World 2004; Fall: 9-17
4. Smith DA, Schmid EF. Drug withdrawals and the lessons within. Curr Opin Drug Discov Devel 2006 Jan; 9 (1): 38-46
5. Horton R. Vioxx, the implosion of Merck and aftershocks at the FDA. Lancet 2004; 364: 1995-6
6. Lang L. Valdecoxib (Bextra) withdrawal leaves pain relief treatment gap. Gastroenterology 2005; 128: 1769-70
7. Keun HC, Athersuch TJ. Application of metabonomics in drug development. Pharmacogenomics 2007 Jul; 8 (7): 731-41
8. Nicholson JK, Connelly J, Lindon JC, et al. Metabonomics: a platform for studying drug toxicity and gene function. Nat Rev Drug Discov 2002 Feb; 1 (2): 153-61
9. Dunn WB, Bailey NJ, Johnson HE. Measuring the metabolome: current analytical technologies. Analyst 2005 May; 130 (5): 606-25
10. Ellis DI, Goodacre R. Metabolic fingerprinting in disease diagnosis: biomedical applications of infrared and Raman spectroscopy. Analyst 2006 Aug; 131 (8): 875-85
11. Kristal BS, Shurubor YI, Kaddurah-Daouk R, et al. High-performance liquid chromatography separations coupled with coulometric electrode array detectors: a unique approach to metabolomics. Methods Mol Biol 2007; 358: 159-74
12. Beckonert O, Keun HC, Ebbels TM, et al. Metabolic profiling, metabolomic and metabonomic procedures for NMR spectroscopy of urine, plasma, serum and tissue extracts. Nat Protoc 2007; 2 (11): 2692-703
13. Mashego MR, Rumbold K, De Mey M, et al. Microbial metabolomics: past, present and future methodologies. Biotechnol Lett 2007 Jan; 29 (1): 1-16
14. Wishart DS. Current progress in computational metabolomics. Brief Bioinform 2007 Sep; 8 (5): 279-93
15. Wishart DS. Quantitative metabolomics using NMR. Trends Analyt Chem 2008 Mar; 27 (20): 228-37
16. Trygg J, Holmes E, Lundstedt T. Chemometrics in metabonomics. J Proteome Res 2007 Feb; 6 (2): 469-79
17. Weljie AM, Newton J, Mercier P, et al. Targeted profiling: quantitative analysis of 1H NMR metabolomics data. Anal Chem 2006 Jul 1; 78 (13): 4430-42
18. Wishart DS, Knox C, Guo AC, et al. DrugBank: a comprehensive resource for in silico drug discovery and exploration. Nucleic Acids Res 2006 Jan 1; 34 (Database issue): D668-72
19. Mahidol C, Ruchirawat S, Prawat H, et al. Biodiversity and natural product drug discovery. Pure Appl Chem 1998; 70: 2065-72
20. Newman DJ, Cragg GM. Natural products as sources of new drugs over the last 25 years. J Nat Prod 2007 Mar; 70 (3): 461-77
21. Wishart DS, Tzur D, Knox C, et al. HMDB: the Human Metabolome Database. Nucleic Acids Res 2007 Jan; 35 (Database issue): D521-6
22. Hegeman AD, Schulte CF, Cui Q, et al. Stable isotope assisted assignment of elemental compositions for metabolomics. Anal Chem 2007 Sep 15; 79 (18): 6912-21
23. van der Werf MJ, Overkamp KM, Muilwijk B, et al. Microbial metabolomics: toward a platform with full metabolome coverage. Anal Biochem 2007 Nov 1; 370 (1): 17-25
24. Moco S, Bino RJ, Vorst O, et al. A liquid chromatography-mass spectrometry-based metabolome database for tomato. Plant Physiol 2006 Aug; 141 (4): 1205-18
25. Krug D, Zurek G, Revermann O, et al. Discovering the hidden secondary metabolome of Myxococcus xanthus: a study of intraspecific diversity. Appl Environ Microbiol 2008 May; 74 (10): 3058-68
26. Angelova N, Kong HW, van der Heijden R, et al. Recent methodology in the phytochemical analysis of ginseng. Phytochem Anal 2008 Jan-Feb; 19 (1): 2-16
27. Steinbeck C. Recent developments in automated structure elucidation of natural products. Nat Prod Rep 2004 Aug; 21 (4): 512-8
28. Cloarec O, Dumas ME, Craig A, et al. Statistical total correlation spectroscopy: an exploratory approach for latent biomarker identification from metabolic 1H NMR data sets. Anal Chem 2005 Mar 1; 77 (5): 1282-9
29. Kind T, Fiehn O. Seven golden rules for heuristic filtering of molecular formulas obtained by accurate mass spectrometry. BMC Bioinformatics 2007 Mar 27; 8: 105
30. Herebian D, Küpper U, Schomburg D, et al. In vivo labeling with stable isotopes as a tool for the identification of unidentified peaks in the metabolome analysis of Corynebacterium glutamicum by GC/MS. Biol Chem 2007 Aug; 388 (8): 865-71
31. Bradshaw J, Butina D, Dunn AJ, et al. A rapid and facile method for the dereplication of purified natural products. J Nat Prod 2001 Dec; 64 (12): 1541-4
32. Thurman EM, Ferrer I, Fernández-Alba AR. Matching unknown empirical formulas to chemical structure using LC/MS TOF accurate mass and database searching: example of unknown pesticides on tomato skins. J Chromatogr A 2005 Mar 4; 1067 (1-2): 127-34
33. Konishi Y, Kiyota T, Draghici C, et al. Molecular formula analysis by an MS/MS/MS technique to expedite dereplication of natural products. Anal Chem 2007 Feb 1; 79 (3): 1187-97
34. Elyashberg ME, Blinov KA, Williams AJ, et al. Structure elucidator: a versatile expert system for molecular structure elucidation from 1D and 2D NMR data and molecular fragments. J Chem Inf Comput Sci 2004 May-Jun; 44 (3): 771-92
35. Kanehisa M, Goto S, Hattori M, et al. From genomics to chemical genomics: new developments in KEGG. Nucleic Acids Res 2006 Jan 1; 34 (Database issue): D354-7
36. Ehrman TM, Barlow DJ, Hylands PJ. Phytochemical databases of Chinese herbal constituents and bioactive plant compounds with known target specificities. J Chem Inf Model 2007 Mar-Apr; 47 (2): 254-63
37. Duke J. USDA Germplasm Resources Information Network (GRIN): Dr Duke's phytochemical and ethnobotanical databases [online]. Available from URL: http://www.ars-grin.gov/duke/ [Accessed 2008 Apr 20]
38. Ehrman TM, Barlow DJ, Hylands PJ. Virtual screening of Chinese herbs with Random Forest. J Chem Inf Model 2007 Mar-Apr; 47 (2): 264-78
39. Rollinger JM, Haupt S, Stuppner H, et al. Combining ethnopharmacology and virtual screening for lead structure discovery: COX-inhibitors as application example. J Chem Inf Comput Sci 2004 Mar-Apr; 44 (2): 480-8
40. Anishetty S, Pulimi M, Pennathur G. Potential drug targets in Mycobacterium tuberculosis through metabolic pathway analysis. Comput Biol Chem 2005 Oct; 29 (5): 368-78
41. Wishart DS. Human Metabolome Database: completing the 'human parts list'. Pharmacogenomics 2007 Jul; 8 (7): 683-6
42. Wishart DS. Drug-target discovery in silico: using the web to identify novel molecular targets for drug action. SEB Exp Biol Ser 2007; 58: 145-76
43. Tietz NW, editor. Clinical guide to laboratory tests. 3rd ed. Philadelphia (PA): WB Sanders Press, 1995
44. Brindle JT, Nicholson JK, Schofield PM, et al. Application of chemometrics to 1H NMR spectroscopic data to investigate a relationship between human serum metabolic profiles and hypertension. Analyst 2003 Jan; 128 (1): 32-6
45. Dunn WB, Broadhurst DI, Deepak SM, et al. Serum metabolomics reveals many novel metabolic markers of heart failure, including pseudouridine and 2-oxoglutarate. Metabolomics 2007 Dec; 3 (4): 413-26
46. Bogdanov M, Matson WR, Wang L, et al. Metabolomic profiling to develop blood biomarkers for Parkinson's disease. Brain 2008 Feb; 131 (Pt 2): 389-96
47. Serkova NJ, Gamito EJ, Jones RH, et al. The metabolites citrate, myo-inositol, and spermine are potential age-independent markers of prostate cancer in human expressed prostatic secretions. Prostate 2008 May 1; 68 (6): 620-8
48. Fan X, Bai J, Shen P. Diagnosis of breast cancer using HPLC metabonomics fingerprints coupled with computational methods. Conf Proc IEEE Eng Med Biol Soc 2005; 6: 6081-4
49. Odunsi K, Wollman RM, Ambrosone CB, et al. Detection of epithelial ovarian cancer using 1H-NMR-based metabonomics. Int J Cancer 2005 Feb 20; 113 (5): 782-8
50. Kaddurah-Daouk R. Metabolic profiling of patients with schizophrenia. PLoS Med 2006 Aug; 3 (8): e363
51. Han X, M Holtzman D, McKeel Jr DW, et al. Substantial sulfatide deficiency and ceramide elevation in very early Alzheimer's disease: potential role in disease pathogenesis. J Neurochem 2002 Aug; 82 (4): 809-18
52. Brindle JT, Antti H, Holmes E, et al. Rapid and noninvasive diagnosis of the presence and severity of coronary heart disease using 1H-NMR-based metabonomics. Nat Med 2002 Dec; 8 (12): 1439-44
53. Moolenaar SH, Engelke UF, Wevers RA. Proton nuclear magnetic resonance spectroscopy of body fluids in the field of inborn errors of metabolism. Ann Clin Biochem 2003 Jan; 40 (Pt 1): 16-24
54. Kuhara T. Noninvasive human metabolome analysis for differential diagnosis of inborn errors of metabolism. J Chromatogr B Analyt Technol Biomed Life Sci 2007 Aug; 855 (1): 42-50
55. Morvan D, Demidem A. Metabolomics by proton nuclear magnetic resonance spectroscopy of the response to chloroethylnitrosourea reveals drug efficacy and tumor adaptive metabolic pathways. Cancer Res 2007 Mar 1; 67 (5): 2150-9
56. Wishart DS. Improving early drug discovery through ADME modelling: an overview. Drugs R D 2007; 8 (6): 349-62
57. Marathe PH, Shyu WC, Humphreys WG. The use of radio-labeled compounds for ADME studies in discovery and exploratory development. Curr Pharm Des 2004; 10 (24): 2991-3008
58. Chu I, Nomeir AA. Utility of mass spectrometry for in-vitro ADME assays. Curr Drug Metab 2006 Jun; 7 (5): 467-77
59. Prakash C, Shaffer CL, Nedderman A. Analytical strategies for identifying drug metabolites. Mass Spectrom Rev 2007 May-Jun; 26 (3): 340-69
60. Chen C, Gonzalez FJ, Idle JR. LC-MS-based metabolomics in drug metabolism. Drug Metab Rev 2007; 39 (2-3): 581-97
61. Pole DL, Ando HY, Murphy ST. Prediction of drug degradants using DELPHI: an expert system for focusing knowledge. Mol Pharm 2007 Jul-Aug; 4 (4): 539-49
62. Testa B, Balmat AL, Long A, et al. Predicting drug metabolism: an evaluation of the expert system METEOR. Chem Biodivers 2005 Jul; 2 (7): 872-85
63. Ridder L, Wagener M. SyGMa: combining expert knowledge and empirical scoring in the prediction of metabolites. ChemMedChem 2008 May; 3 (5): 821-32
64. Stranz DD, Miao S, Campbell S, et al. Combined computational metabolite prediction and automated structure-based analysis of mass spectrometric data. Toxicol Mech Methods 2008 Feb; 18 (2): 243-50
65. Roslund MU, Tähtinen P, Niemitz M, et al. Complete assignments of the (1)H and (13)C chemical shifts and J(H,H) coupling constants in NMR spectra of D-glucopyranose and all D-glucopyranosyl-D-glucopyranosides. Carbohydr Res 2008 Jan; 343 (1): 101-12
66. Klagkou K, Pullen F, Harrison M, et al. Approaches towards the automated interpretation and prediction of electrospray tandem mass spectra of non-peptidic combinatorial compounds. Rapid Commun Mass Spectrom 2003; 17 (11): 1163-8
67. Mortishire-Smith RJ, O'Connor D, Castro-Perez JM, et al. Accelerated throughput metabolic route screening in early drug discovery using high-resolution liquid chromatography/quadrupole time-of-flight mass spectrometry and automated data analysis. Rapid Commun Mass Spectrom 2005; 19 (18): 2659-70
68. Holmes E, Loo RL, Cloarec O, et al. Detection of urinary drug metabolite (xenometabolome) signatures in molecular epidemiology studies via statistical total correlation (NMR) spectroscopy. Anal Chem 2007 Apr 1; 79 (7): 2629-40
69. Bateman KP, Castro-Perez J, Wrona M, et al. MSE with mass defect filtering for in vitro and in vivo metabolite identification. Rapid Commun Mass Spectrom 2007; 21 (9): 1485-96
70. Giri S, Idle JR, Chen C, et al. A metabolomic approach to the metabolism of the areca nut alkaloids arecoline and arecaidine in the mouse. Chem Res Toxicol 2006 Jun; 19 (6): 818-27
71. Fandiño AS, Nägele E, Perkins PD. Automated software-guided identification of new buspirone metabolites using capillary LC coupled to ion trap and TOF mass spectrometry. J Mass Spectrom 2006 Feb; 41 (2): 248-55
72. Keun HC, Athersuch TJ, Beckonert O, et al. Heteronuclear 19F-1H statistical total correlation spectroscopy as a tool in drug metabolism: study of flucloxacillin biotransformation. Anal Chem 2008 Feb 15; 80 (4): 1073-9
73. Nicholson JK, Wilson ID. High resolution nuclear magnetic resonance spectroscopy of biological samples as an aid to drug development. Prog Drug Res 1987; 31: 427-9
74. Lindon JC, Holmes E, Nicholson JK. Metabonomics in pharmaceutical R&D. FEBS J 2007 Mar; 274 (5): 1140-51
75. Ebbels TM, Keun HC, Beckonert OP, et al. Prediction and classification of drug toxicity using probabilistic modeling of temporal metabolic data: the consortium on metabonomic toxicology screening approach. J Proteome Res 2007 Nov; 6 (11): 4407-22
76. Williams RE, Major H, Lock EA, et al. D-Serine-induced nephrotoxicity: a HPLC-TOF/MS-based metabonomics approach. Toxicology 2005; 207: 179-90
77. Lenz EM, Bright J, Knight R, et al. Metabonomics with 1H-NMR spectroscopy and liquid chromatography-mass spectrometry applied to the investigation of metabolic changes caused by gentamicin-induced nephrotoxicity in the rat. Biomarkers 2005; 10: 173-87
78. Lindon JC, Holmes E, Bollard ME, et al. Metabonomics technologies and their applications in physiological monitoring, drug safety assessment and disease diagnosis. Biomarkers 2004; 9: 1-31
79. Lenz EM, Bright J, Knight R, et al. A metabonomic investigation of the biochemical effects of mercuric chloride in the rat using 1H NMR and HPLC-TOF/MS: time dependent changes in the urinary profile of endogenous metabolites as a result of nephrotoxicity. Analyst 2004; 129: 535-41
80. Robertson DG, Reily MD, Baker JD. Metabonomics in pharmaceutical discovery and development. J Proteome Res 2007 Feb; 6 (2): 526-39
81. Robertson DG, Reily MD, Albassam M, et al. Metabonomic assessment of vasculitis in rats. Cardiovasc Toxicol 2001; 1 (1): 7-19
82. Dieterle F, Ross A, Schlotterbeck G, et al. Metabolite projection analysis for fast identification of metabolites in metabonomics: application in an amiodarone study. Anal Chem 2006 Jun 1; 78 (11): 3551-61
83. Connor SC, Hodson MP, Ringeissen S, et al. Development of a multivariate statistical model to predict peroxisome proliferation in the rat, based on urinary 1H-NMR spectral patterns. Biomarkers 2004 Jul-Oct; 9 (4-5): 364-85
84. Mennen LI, Sapinho D, Ito H, et al. Urinary flavonoids and phenolic acids as biomarkers of intake for polyphenol-rich foods. Br J Nutr 2006 Jul; 96 (1): 191-8
85. van den Bout-van den Beukel CJ, Koopmans PP, van der Ven AJ, et al. Possible drug-metabolism interactions of medicinal herbs with antiretroviral agents. Drug Metab Rev 2006; 38 (3): 477-514
86. Dervieux T, Meshkin B, Neri B. Pharmacogenetic testing: proofs of principle and pharmacoeconomic implications. Mutat Res 2005 Jun 3; 573 (1-2): 180-94
87. Thuerauf N, Lunkenheimer J. The impact of the CYP2D6-polymorphism on dose recommendations for current antidepressants. Eur Arch Psychiatry Clin Neurosci 2006 Aug; 256 (5): 287-93
88. Frye RF, Matzke GR, Adedoyin A, et al. Validation of the five-drug "Pittsburgh cocktail" approach for assessment of selective regulation of drug-metabolizing enzymes. Clin Pharmacol Ther 1997 Oct; 62 (4): 365-76
89. Dervieux T, Meyer G, Barham R, et al. Liquid chromatography-tandem mass spectrometry analysis of erythrocyte thiopurine nucleotides and effect of thiopurine methyltransferase gene variants on these metabolites in patients receiving azathioprine/6-mercaptopurine therapy. Clin Chem 2005 Nov; 51 (11): 2074-84
90. Coe RA, Rathe JO, Lee JW. Supercritical fluid chromatography-tandem mass spectrometry for fast bioanalysis of R/S-warfarin in human plasma. J Pharm Biomed Anal 2006 Nov 16; 42 (5): 573-80
91. Vollenbroeker B, Koch JH, Fobker M, et al. Determination of cyclosporine and its metabolites in blood via HPLC-MS and correlation to clinically important parameters. Transplant Proc 2005; 37: 1741-4
92. Annesley TM, Clayton LT. Quantification of mycophenolic acid and glucuronide metabolite in human serum by HPLC-tandem mass spectrometry. Clin Chem 2005; 51: 872-7
93. Lazarou J, Pomeranz BH, Corey PN. Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. JAMA 1998 Apr 15; 279 (15): 1200-5
94. Kaddurah-Daouk R, McEvoy J, Baillie RA, et al. Metabolomic mapping of atypical antipsychotic effects in schizophrenia. Mol Psychiatry 2007 Oct; 12 (10): 934-45
95. van Doorn M, Vogels J, Tas A, et al. Evaluation of metabolite profiles as biomarkers for the pharmacological effects of thiazolidinediones in type 2 diabetes mellitus patients and healthy volunteers. Br J Clin Pharmacol 2007 May; 63 (5): 562-74
96. Serkova NJ, Christians U. Biomarkers for toxidynamic monitoring of immunosuppressants: NMR-based quantitative metabonomics of the blood. Ther Drug Monit 2005; 27: 733-7
97. Stapenhorst L, Sassen R, Beck B, et al. Hypocitraturia as a risk factor for nephrocalcinosis after kidney transplantation. Pediatr Nephrol 2005; 20: 652-6
98. Tse KC, Lam MF, Yip PS, et al. A long-term study on hyperlipidemia in stable renal transplant recipients. Clin Transplant 2004; 18: 274-80
99. Moreno JM, Ruiz MC, Ruiz N, et al. Modulation factors of oxidative status in stable renal transplantation. Transplant Proc 2005; 37: 1428-30
100. Teutonico A, Schena PF, Di Paolo S. Glucose metabolism in renal transplant recipients: effect of calcineurin inhibitor withdrawal and conversion to sirolimus. J Am Soc Nephrol 2005; 16: 3128-35
101. Kanbay M, Akcay A, Huddam B, et al. Influence of cyclosporine and tacrolimus on serum uric acid levels in stable kidney transplant recipients. Transplant Proc 2005; 37: 3119-20
102. Wong W, Tolkoff-Rubin N, Delmonico FL, et al. Analysis of the cardiovascular risk profile in stable kidney transplant recipients after 50% cyclosporine reduction. Clin Transplant 2004; 18: 341-8